Statera Biopharma Inc Fka Cytocom Inc Revenue Growth Rates (STAB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Statera Biopharma Inc fka Cytocom Inc   (NASDAQ: STAB)
 

STAB's Revenue Growth by Quarter and Year

Statera Biopharma Inc Fka Cytocom Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

STAB Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 0.67
2nd Quarter June 0.77
1st Quarter March 1.00
FY 2.44

STABs Annual Revenue
Statera Biopharma Inc Fka Cytocom Inc 's Revenue in the fiscal year 2021 $ 1.49 millions
Statera Biopharma Inc Fka Cytocom Inc 's Revenue in the fiscal year 2020 $ 0.26 millions
Statera Biopharma Inc Fka Cytocom Inc 's Revenue in the fiscal year 2019 $ 0.92 millions
Statera Biopharma Inc Fka Cytocom Inc 's Revenue in the fiscal year 2018 $ 1.14 millions
Statera Biopharma Inc Fka Cytocom Inc 's Revenue in the fiscal year 2017 $ 1.95 millions




STAB Revenue third quarter 2022 Y/Y Growth Comment
Statera Biopharma Inc fka Cytocom Inc achieved in the third quarter 2022, above Company average Revenue surge of 179.36% year on year, to $ 0.67 millions.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue growth. While Statera Biopharma Inc Fka Cytocom Inc ' s Revenue doubling of 179.36% ranks overall at the positon no. 224 in the third quarter 2022.


STAB Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - - - -25 %
3rd Quarter September 179.36 % 500 % -85.19 % -3.57 %
2nd Quarter June - - -78.57 % -28.21 %
1st Quarter March - - -20 % -13.04 %
FY   - 473.08 % -72.04 % -

Financial Statements
Statera Biopharma Inc Fka Cytocom Inc 's third quarter 2022 Revenue $ 0.67 millions STAB's Income Statement
Statera Biopharma Inc Fka Cytocom Inc 's third quarter 2021 Revenue $ 0.24 millions Quarterly STAB's Income Statement


STAB Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 420.83 % - -33.33 %
3rd Quarter September -12.93 % - -33.33 % -3.57 %
2nd Quarter June -23 % - -62.5 % 40 %
1st Quarter March -20 % - -11.11 % -16.67 %
FY (Year on Year)   - 473.08 % -72.04 % -


Back to STAB Growth rate Comparisons >> Back to STAB Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #66
Overall #224

Revenue Y/Y Growth Statistics
High Average Low
644.89 % 29.54 % -100 %
(Sep 30 2013)   (Jun 30 2021)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #66
Overall #224
Revenue Y/Y Growth Statistics
High Average Low
644.89 % 29.54 % -100 %
(Sep 30 2013)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Statera Biopharma Inc Fka Cytocom Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
884.4 % 28.47 % -100 %
(Dec 31 2012)  


STAB's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Statera Biopharma Inc Fka Cytocom Inc disclosed drop in Revenue from the second quarter by -12.93% to $ 0.67 millions, from $ 0.77 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 227 other companies have achieved higher Revenue quarter on quarter growth. While Statera Biopharma Inc Fka Cytocom Inc 's Revenue growth quarter on quarter, overall rank is 3893.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #228
Healthcare Sector #596
Overall #3893
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #228
Healthcare Sector #596
Overall #3893
Revenue Q/Q Growth Statistics
High Average Low
884.4 % 28.47 % -100 %
(Dec 31 2012)  


STAB's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Statera Biopharma Inc Fka Cytocom Inc disclosed drop in Revenue from the second quarter by -12.93% to $ 0.67 millions, from $ 0.77 millions achived in the previous reporting period.

Within Major Pharmaceutical Preparations industry 227 other companies have achieved higher Revenue quarter on quarter growth. While Statera Biopharma Inc Fka Cytocom Inc 's Revenue growth quarter on quarter, overall rank is 3893.


Statera Biopharma Inc Fka Cytocom Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 3.69 $ 3.25 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 13.34 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 1768 # 0 # 0 # 0 # 3208


Cumulative Revenue growth Comment
Statera Biopharma Inc Fka Cytocom Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 179.36% year on year, to $ 4 millions if the fiscal year would have ended in Sep 30 2022.
Statera Biopharma Inc Fka Cytocom Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2022. And, Statera Biopharma Inc Fka Cytocom Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Jun 30 2022 rise was beneth at 13.34 % from $3.25 millions achieved in the period from Jun 30 2022 to Sep 30 2021.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -13.87%.

Statera Biopharma Inc fka Cytocom Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 253
S&P 500 # 1768
Cumulative Revenue growth Comment
Statera Biopharma Inc Fka Cytocom Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 179.36% year on year, to $ 4 millions if the fiscal year would have ended in Sep 30 2022.
Statera Biopharma Inc Fka Cytocom Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2022. And, Statera Biopharma Inc Fka Cytocom Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Jun 30 2022 rise was beneth at 13.34 % from $3.25 millions achieved in the period from Jun 30 2022 to Sep 30 2021.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -13.87%.
The momentum is even more impressive from twelve months ended Jun 30 2022 exhibited at 13.34 % increase from $3.25 millions in the period from Jun 30 2022 to Sep 30 2021.

Statera Biopharma Inc fka Cytocom Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 106
Sector # 253
S&P 500 # 1768




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
STAB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Novavax inc 310.74%$ 310.736 millions
Apellis Pharmaceuticals Inc 290.37%$ 290.372 millions
Babylon Holdings Limited287.98%$ 287.980 millions
Aurinia Pharmaceuticals Inc 280.30%$ 280.303 millions
Sera Prognostics Inc 278.26%$ 278.261 millions
Mirum Pharmaceuticals Inc 275.60%$ 275.600 millions
Evofem Biosciences Inc 272.14%$ 272.138 millions
Fresh Tracks Therapeutics Inc 268.18%$ 268.182 millions
Talis Biomedical Corporation265.14%$ 265.138 millions
Biorestorative Therapies Inc 262.50%$ 262.500 millions
Vir Biotechnology Inc 261.49%$ 261.486 millions
Igc Pharma Inc 260.71%$ 260.714 millions
Arvinas Inc 257.57%$ 257.574 millions
Arcus Biosciences Inc 254.94%$ 254.941 millions
Ideaya Biosciences Inc 230.87%$ 230.871 millions
Agape Atp Corporation229.81%$ 229.806 millions
Intra cellular Therapies Inc 223.63%$ 223.634 millions
Pear Therapeutics Inc 211.44%$ 211.442 millions
Revolution Medicines Inc 204.81%$ 204.814 millions
Harpoon Therapeutics Inc 203.68%$ 203.680 millions
Scynexis Inc 201.74%$ 201.744 millions
Tenon Medical Inc 197.14%$ 197.143 millions
Vbi Vaccines Inc196.26%$ 196.262 millions
Sutro Biopharma Inc 195.26%$ 195.257 millions
Statera Biopharma Inc fka Cytocom Inc 183.48%$ 183.475 millions
Bolt Biotherapeutics Inc 180.85%$ 180.851 millions
Rennova Health Inc 179.73%$ 179.728 millions
Hoth Therapeutics Inc 177.78%$ 177.775 millions
Geron Corporation172.48%$ 172.477 millions
Xeris Biopharma Holdings Inc 168.76%$ 168.761 millions


About Statera Biopharma Inc Fka Cytocom Inc Revenue Growth Rates (STAB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Statera Biopharma Inc (CIK 1318641).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-22-027371
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Statera Biopharma Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.